These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29187427)

  • 21. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
    Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
    Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
    Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
    Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
    BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen blockade based clinical trials landscape in triple negative breast cancer.
    Shi Y; Yang F; Huang D; Guan X
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):283-290. PubMed ID: 29807045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
    Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
    Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
    Hilborn E; Gacic J; Fornander T; Nordenskjöld B; Stål O; Jansson A
    Br J Cancer; 2016 Feb; 114(3):248-55. PubMed ID: 26742006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.
    Asemota S; Effah W; Young KL; Holt J; Cripe L; Ponnusamy S; Thiyagarajan T; Hwang DJ; He Y; Mcnamara K; Johnson D; Wang Y; Grimes B; Khosrosereshki Y; Hollingsworth TJ; Fleming MD; Pritchard FE; Hendrix A; Khan F; Fan M; Makowski L; Yin Z; Sasano H; Hayes DN; Pfeffer LM; Miller DD; Narayanan R
    Cell Rep; 2023 Dec; 42(12):113461. PubMed ID: 37979170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complexities of androgen receptor signalling in breast cancer.
    McNamara KM; Moore NL; Hickey TE; Sasano H; Tilley WD
    Endocr Relat Cancer; 2014 Aug; 21(4):T161-81. PubMed ID: 24951107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
    Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
    Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
    Wu Y; Xue J; Li J
    Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor in triple negative breast cancer.
    McNamara KM; Yoda T; Takagi K; Miki Y; Suzuki T; Sasano H
    J Steroid Biochem Mol Biol; 2013 Jan; 133():66-76. PubMed ID: 22982153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
    Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
    Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
    Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J
    Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.